![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JH Bowdre, JH Hull and DM Cocchetto
Seven antimicrobial agents, all effective against Vibrio vulnificus in vitro, were compared for in vivo efficacy in mice experimentally infected with V. vulnificus strain B3547. Mice were injected s.c. with 1 X 10(8) cells, and i.p. injection of antimicrobials was begun 1.5 hr later when mice were bacteremic and had edematous lesions at the injection site. The study was done in two phases. Phase I was a dose- ranging experiment, using single injections within the range (on a body weight-adjusted basis) clinically useful in humans. Of 12 mice treated with tetracycline (4 mg/kg), 12 survived at 24 hr, compared to 0 of 21 saline-treated controls, 3 of 10 given ampicillin (32 mg/kg) and 2 of 3 given cefotaxime (20 mg/kg). There were no survivors at 24 hr in groups of 5 to 10 mice treated with cefazolin (32 mg/kg), carbenicillin (80 mg/kg), erythromycin (8 mg/kg) or gentamicin (8 mg/kg). Phase II was designed to simulate clinical conditions using multiple dosing for 30 hr and scoring for survival at 96 hr. Of 12 mice given tetracycline (3 mg/kg every 12 hr), 12 survived, compared to 1 of 10 given cefotaxime (20 mg/kg every 6 hr), 0 of 12 given carbenicillin (40 mg/kg every 6 hr) and 0 of 12 given saline every 6 hr. Tetracycline thus appears to be the agent of choice among those tested for in vivo efficacy against V. vulnificus in the mouse model.
This article has been cited by other articles:
|
|
 |
|
  J.-W. Liu, I.-K. Lee, H.-J. Tang, W.-C. Ko, H.-C. Lee, Y.-C. Liu, P.-R. Hsueh, and Y.-C. Chuang Prognostic Factors and Antibiotics in Vibrio vulnificus Septicemia. Arch Intern Med, October 23, 2006; 166(19): 2117 - 2123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-M. Kim, Y. Lym, S. J. Jang, H. Han, Y. G. Kim, C.-H. Chung, and S. P. Hong In Vitro Efficacy of the Combination of Ciprofloxacin and Cefotaxime against Vibrio vulnificus Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3489 - 3491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Tang, M.-C. Chang, W.-C. Ko, K.-Y. Huang, C.-L. Lee, and Y.-C. Chuang In Vitro and In Vivo Activities of Newer Fluoroquinolones against Vibrio vulnificus Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3580 - 3584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lee, S. Y. Kim, S. J. Kim, H. S. Kim, J. H. Shin, S. H. Choi, S. S. Chung, and J. H. Rhee Direct Identification of Vibrio vulnificus in Clinical Specimens by Nested PCR J. Clin. Microbiol., October 1, 1998; 36(10): 2887 - 2892. [Abstract] [Full Text]
|
|
|
|
|
|
Y.-C. Chuang, W.-C. Ko, S.-T. Wang, J.-W. Liu, C.-F. Kuo, J.-J. Wu, and K.-Y. Huang Minocycline and Cefotaxime in the Treatment of Experimental Murine Vibrio vulnificus Infection Antimicrob. Agents Chemother., June 1, 1998; 42(6): 1319 - 1322. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. S. Warren and E. M. Bailey Case 41-1994- A 57-Year-Old Man with Chronic Active Hepatitis, a Rapidly Progressive Bullous Eruption, and Shock N. Engl. J. Med., November 17, 1994; 331(20): 1362 - 1368. [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
